International Medicine (000516.SZ) announced its 2023 annual results forecast, which is expected to be owned by shareholders of listed companies for the whole year...
According to the Zhitong Finance App, International Medicine (000516.SZ) released its 2023 annual results forecast. The net loss attributable to shareholders of listed companies is expected to be 280 million yuan to 370 million yuan for the whole year.
The main reasons for the loss in performance are: 1. During the reporting period, with the introduction of the company's newly built hospitals and new business development, it effectively met multi-level and diversified medical needs, which led to a rapid increase in business scale, and the company's revenue increased significantly over the same period last year. 2. During the reporting period, the overall usage of medical beds built by the company increased steadily, the asset structure was further optimized, and the gross margin level continued to improve. However, operating costs and period expenses also increased to a certain extent, and the scale of operating income did not cover operating costs and period expenses.